Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after one-year of treatment: real-world practice.

There are no studies which directly compare efficacy in PASI response of secukinumab and ixekizumab. The main aim of this study was to compare the efficacy and safety of both drugs used to treat moderate-to-severe psoriasis patients over 52 weeks. Secondary objectives were to identify which factors related to prior biologic treatment influenced their efficacy, and analyze data obtained at 12 weeks. A retrospective observational study was carried out, in which a group of the first 59 patients treated with secukinumab after its commercialization, was compared with another group of the first 29 patients treated with ixekizumab. The PASI 75, 90 and 100 response obtained at 52 weeks was 64.4%, 49.2%, 41.4% for secukinumab and 75.9%, 62.1% and 41.4% for ixekizumab, with no statistically significant differences. Regarding previous biological treatment, both treatments showed a decrease in efficacy as the number of prior biologics increases. No differences were found between secukinumab and ixekizumab in bio-naive or bio-experienced patients, with the exception of a higher PASI 75 response at week 52 for ixekizumab in those patients with 2 or more previous biologics (P = 0'039) Secukinumab and ixekizumab have demonstrated high efficacy and safety, with no statistically significant differences. This article is protected by copyright. All rights reserved.